Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;12(1):15-24.
doi: 10.2174/138920211794520132.

Genetic and epigenetic alterations in pancreatic carcinogenesis

Affiliations

Genetic and epigenetic alterations in pancreatic carcinogenesis

Yannick Delpu et al. Curr Genomics. 2011 Mar.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.

Keywords: Cancer; DNA methylation; Genetic alteration.; Pancreas; Preneoplastic lesions.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Microscopic view of Pancreatic intraepithelial neoplasia.
Fig. (2)
Fig. (2)
A: Macroscopic view of an Intraductal Papillary Mucinous Neoplasm. B: Microscopic view of an Intraductal Papillary Mucinous Neoplasm.
Fig. (3)
Fig. (3)
A: Macroscopic view of Mucinous Cystic Neoplasm. B: Microscopic view of Mucinous Cystic Neoplasm.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. CA Cancer J. Clin. 2009;59:225–249. - PubMed
    1. Koorstra J B, Hustinx S R, Offerhaus G J, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110–125. - PMC - PubMed
    1. Ghaneh P, Costello E, Neoptolemos J P. Biology and management of pancreatic cancer. Gut. 2007;56:1134–1152. - PMC - PubMed
    1. Brat D J, Lillemoe K D, Yeo C J, Warfield P B, Hruban R H. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 1998;22:163–169. - PubMed
    1. Hruban R H, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 2008;1:306–316. - PMC - PubMed